Immune Reset

The concept that deep B-cell depletion via CAR-T or T-cell engagers can “reboot” the immune system — producing drug-free remissions in autoimmune diseases. Not classical immunosuppression, but a system-level reset followed by naive B-cell repopulation.

Evidence

• Carl June (Penn) and Georg Schett / Fabian Müller (Erlangen): CD19 4-1BBζ CAR in refractory lupus → cutaneous disease cleared in ~1 month; longest ongoing remission >3 years, drug-free
• Sadelain: Mackensen and Schett gave refractory SLE patients the same CD19 CAR built for leukemia — dramatic improvement, immunosuppression discontinued
• ~300 CAR-T trials for autoimmunity now active — exponential growth
• Trials across SLE, RA, JIA, myasthenia gravis, NMO, stiff-person syndrome, inflammatory myopathies

Mechanism

• Complete B-cell ablation followed by naive repopulation
• Reconstituted B cells display a naive phenotype — immune memory has been reset
• Striking inversion: B-cell aplasia (the on-target side effect tolerated in oncology) is now the therapeutic mechanism

Open Questions

• Duration — the key unknown (June: “What we don’t know yet is duration”)
• Safety when applying oncology modalities to autoimmunity (where profound safety is required)
• Whether “one-and-done” therapy is achievable

Cross-References

• CAR-T therapy — the modality
• Lupus — primary indication
• Robert Plenge (BMS) — registrational CD19 CAR-T for lupus (Session IX)
• Gilead — gamgertamig (T-cell engager approach to same concept)